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Background: Arterial oxygen tension, oxygen delivery to tissue, and systemic inﬂ  ammation 
are recognized as pivotal factors in the progression of chronic obstructive pulmonary disease 
(COPD). However, interconnections between systemic inﬂ  ammation and tissue oxygen 
availability are scantly investigated. Tissue oxygen availability depends on arterial PaO2, oxygen 
concentration, hemoglobin oxygen afﬁ  nity (P50), and hemoglobin oxygen binding capacity 
(ceHb). As the integrated changes of those indices are summarized by oxygen extraction tension 
(PaO2x), the objective of this study was to explore the association between C-reactive protein 
(CRP) blood levels and either PaO2x or each of its determinants, in stable COPD.
Materials and methods: Blood CRP and oxygen status of arterial blood were measured at rest 
while breathing room air in 44 moderate to severe stable COPD patients. PaO2x was calculated 
along the shape of oxygen binding curve as the oxygen tension resulting from removal of 
2.3 mmol of oxygen per liter of blood. Multiple linear regression analysis was performed with 
PaO2, ceHb, and P50 as independent variables, and CRP as the dependent variable, adjusting for 
age and sex. The analysis was repeated using PaO2x as a sole independent variable.
Results: Multiple linear regression analysis indicated that ceHb, PaO2, and P50, were signiﬁ  cant 
and independent predictors of CRP (R2 = 0.52, p  0.0001). PaO2x alone was an even stronger 
predictor of CRP (R2 = 0.62, p  0.0001).
Conclusions: These ﬁ  ndings indicate that physiological determinants of tissue oxygen 
availability are independently associated with CRP blood levels. Thus, improvement of 
tissue oxygen availability is a central therapeutic option to modulate the severity of systemic 
inﬂ  ammatory processes in patients with COPD.
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Introduction
Systemic inﬂ  ammation (Agustí et al 2003) together with arterial hypoxemia and 
oxygen delivery to tissue (Kawakami et al 1983) are known to inﬂ  uence the prognosis 
of chronic obstructive pulmonary disease (COPD). Nevertheless, whether systemic 
inﬂ  ammatory process is primarily linked to the convective/diffusive process of oxygen 
transport from the lung to tissues or it is just a secondary phenomenon has not been well 
acknowledged yet, as the origin of systemic inﬂ  ammation remains poorly understood 
in patients with COPD (Wouters 2005).
Recently published papers have reported that increased C-reactive protein (CRP) 
blood levels mark the metabolic and functional impairment in patients with stable 
COPD (Schols et al 1996; de Torres et al 2006; Broekhuizen et al 2006; Pinto-Plata 
et al 2006). Previous studies have also documented that wasting syndrome occurs 
in COPD patients with elevated arteriovenous oxygen difference, as a result of low 
arterial and mixed venous oxygenation (Filley et al 1968; Kawakami et al 1983). 
However, Broekhuizen and colleagues (2006) found no difference in arterial oxygen 
tension (PaO2) between patients with normal and raised CRP levels, while de Torres International Journal of COPD 2008:3(4) 746
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and colleagues (2006) found that no more than 20% of the 
variability of CRP is accounted for by PaO2.
It is well acknowledged that hypoxia induces the 
synthesis of inﬂ  ammatory cytokines and the expression 
of adhesion molecules in different cell types and tissues 
in vitro (Ghezzi et al 1991), as well as in humans exposed at 
high altitude (Hartmann et al 2000). We wondered whether 
the severity of systemic inﬂ  ammation, as assessed by CRP 
blood levels, is instead associated with tissue hypoxia 
rather than with arterial hypoxemia alone in patients with 
COPD. To test this hypothesis, we explored the relation-
ship between systemic inﬂ  ammation, as assessed by CRP 
blood levels, and each single determinant of oxygen status 
of arterial blood, ie, PaO2, blood oxygen carrying capacity, 
and blood oxygen afﬁ  nity. We also explored the relationship 
between CRP blood levels, and oxygen extraction tension 
(PaO2x), as this is a noninvasive measurement of periph-
eral oxygen availability, which summarizes the degree of 
compensation among arterial oxygen tension, blood oxygen 
carrying capacity and afﬁ  nity (Siggard-Andersen et al 
1995) and reﬂ  ects changes of cardiac output, which may 
affect extraction ratio and mixed venous oxygen tension 
(Ringsted et al 1990).
Methods
All COPD patients, consecutively referred to our in-patients 
pulmonary rehabilitation center of Montescano, Italy from 
January 2004 to January 2006, were considered eligible for 
the present study. They had to meet the American Thoracic 
Society (ATS) criteria for diagnosis of COPD (Pauwels et al 
2001). Patients were excluded if they had: 1) idiophatic or 
acquired bronchiectasis; 2) COPD exacerbations within the 
last 4 weeks; 3) diagnosed cardiovascular disease (coronary 
artery, peripheral vascular, or cerebrovascular disease); 
4) systemic confounding inﬂ  ammatory disease, such as 
rheumatoid arthritis, psoriatic arthritis, systemic vasculitis, 
polymyalgia rheumatica, Crohn’s disease, or allergic 
complication of infections: eg, erythema nodosum, rheumatic 
fever; 5) malignancies.
Patients had to be clinically stable at the time of examina-
tion (no exacerbation within the last 4 weeks) on a standard 
treatment regimen consisting of inhaled corticosteroids, and 
beta adrenergic, and/or anticholinergic drugs. None of the 
patients had to be on systemic corticosteroids. The pres-
ence of cardiovascular risk factors (hypertension, diabetes, 
hypercholesterolemia) was registered. It was also noted 
whether patients were currently smoking, and whether they 
were on long-term oxygen therapy (LTOT). The Medical 
Ethics Committee at our institution approved the study 
design and a written informed consent was obtained prior 
to the study.
Forced expiratory volume in one second (FEV1), forced 
vital capacity (FVC), inspiratory forced vital capacity (IVC), 
and total lung capacity (TLC) were determined using a Jaeger 
spirometer and body box (Masterlab, Jaeger, Würzburg, 
Germany). FEV1 was also measured 15 minutes after four 
inhalations of salbutamol (400 μg) from a metered-dose 
inhaler. Predicted equations utilized were those of Quanjer 
and colleagues (1993). Carbon monoxide transfer factor 
(TLCO) was measured (Baires System, Biomedin, Padua, 
Italy) using the single breath method and according to the 
ATS recommendation (ATS 1995). Reference equations 
utilized were those of Cotes (1979).
Functional status of the patients was assessed by 
BODE (body mass index, degree of airﬂ  ow obstruction, 
dyspnea, and exercise capacity) index (Celli et al 2004). 
This is a multidimensional grading system based on: 
1) the measurement of body mass index (BMI, Kg/m2); 
2) FEV1, % predicted; 3) degree of dyspnea, measured 
with the modified Medical Research Council (MMRC) 
dyspnea scale; and 4) the evaluation of exercise tolerance, 
as reﬂ  ected by the distance walked at the 6 minute walking 
test (6MWD).
Fasting EDTA blood samples were collected, early in 
the morning (8:00–10:00 hours). CRP was measured in 
duplicate by high sensitivity turbidimetric immuno-assay 
(PETIA) (Dade Behring) with a lower detection limit of 
0.5 mg/L.
Arterial blood samples were gently drawn from the 
brachial artery using a dedicated preheparinized blood 
sampler, while patients were seated and breathing room 
air. Oxygen breathing was temporarily withdrawn for 
at least 30 minutes in patients under oxygen therapy. 
Immediately after sample collection, mixing, and 
removal of the ﬁ  rst drops of blood, the acid-base and 
oxygen status were analyzed. Arterial negative loga-
rithm of hydrogen ion concentration (pH) and arterial 
carbon dioxide tensions (PaCO2), together with arterial 
oxygen tension (PaO2) and the oximetry parameters 
were measured using a blood gas analyzer (ABL Model 
700 System Radiometer, Copenhagen, Denmark). The 
following oximetry parameters were directly mea-
sured: 1) concentration of total hemoglobin in the 
blood (tHb), which includes all types of hemoglobin 
ie, oxy- (O2Hb), deoxy- (HHb), carboxy- (COHb), and 
meta-hemoglobin (MetHb); 2) arterial oxygen saturation International Journal of COPD 2008:3(4) 747
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(sO2) (ie, the ratio between the concentration of O2Hb 
and HHb + O2Hb); 3) fraction of oxyhemoglobin (FO2Hb) 
(ie, the ratio between the concentration of O2Hb and tHb); 
4) fraction of carboxyhemoglobin (FCOHb) (ie, the ratio 
between concentration of COHb and tHb); 5) fraction of 
metahemoglobin (FMetHb) (ie, the ratio between con-
centration of MetHb and tHb); 6) total arterial oxygen 
content (ct O2) (ie, the sum of the concentration of 
hemoglobin-bound oxygen and the concentration of physi-
cally dissolved oxygen). The concentration of effective 
hemoglobin (ceHb) ie, the concentration of total hemoglo-
bin (ctHb) corrected for fractions of carboxyhemoglobin 
(FCOHb) and metahemoglobin (FMetHb), which are 
unable to bind oxygen reversibly was calculated as a mea-
surement of hemoglobin oxygen binding capacity. Both 
oxygen tension at half saturation (50%) of blood (P50), and 
oxygen extraction tension of arterial blood (PaO2x), were 
calculated by extrapolation along the shape of the oxygen 
binding curve on the log PaO2 – ctO2 diagram, by a dedi-
cated computer program (Siggard-Andersen and Siggard-
Andersen 1990). The shape of the curve was modeled on 
the basis of the PaO2 and the hemoglobin oxygen saturation 
fraction meas ured in the arterial blood, using a hyperbolic 
tangent function (Siggaard-Andersen et al 1984).
Statistical analysis
The relationship between CRP and the determinants of 
oxygen extractivity (PaO2, ceHb, and P50) was assessed by 
multiple linear regression analysis, adjusting for age and sex. 
The same analysis was carried out to assess the relationship 
between CRP and PaO2x, the latter being considered as a 
comprehensive index of oxygen availability. Descriptive 
statistics are expressed as mean, standard deviation (SD) or 
median and interquartile range (IQR). A p value 0.05 was 
considered statistically signiﬁ  cant.
Results
A hundred and ﬁ  fty-four patients with COPD were assessed for 
eligibility, and 101 of them were excluded from the analysis 
because they had either concurrent inﬂ  ammatory disease or 
diagnosed cardiovascular disease that may raise CRP blood 
levels. The reasons and the numbers of excluded patients are 
detailed in Figure 1. Nine of the patients refused to participate in 
the study, therefore 44 COPD patients (34 men and 10 women) 
were recruited in the study. Anthropometric and functional 
characteristics are reported in Table 1. Most of the patients 
(41%) were in GOLD stage IV, 93% were exsmokers, and 
1rrent smokers, with a smoking history of 61 ± 31(mean ± SD) 
pack-years.
Figure 1 Flow of eligible COPD participants through the analysis.
Notes: Exclusion criteria: ¶COPD exacerbations within the last 4 weeks; *Diagnosed cardiovascular disease (coronary artery, peripheral vascular, or cerebrovascular disease); 
§Systemic inﬂ  ammatory disease, such as rheumatoid arthritis, psoriatic arthritis, systemic vasculitis, polymyalgia rheumatica, Crohn’s disease, or allergic complication of infections: 
eg, erythema nodosum, rheumatic fever, etc.
Assessed for Eligibility (n = 154)
Idiopathic/acquired Bronchiectasis
(n = 19)
Systemic Inflammatory Diseases§
(n = 9)
COPD Exacerbations¶
(n = 8)
Malignancies
(n = 13)
Analyzed (n = 44)
Refused to participate (n = 9)
Cardiovascular Disease*
(n = 52)
Excluded (n = 101)International Journal of COPD 2008:3(4) 748
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Cardiovascular risk factors were present in 64% of the 
patients. Out of 44, 43% of patients was on LTOT. The 
majority of patients (96%) was on inhaled corticosteroid 
therapy, none of them assumed systemic steroids at the time 
of the study; 61% was on antihypertensive drugs; 7% of 
patients was on statins.
The performance status as assessed by BODE index was 
scored 8 in 16% of patients, indicating a severely impaired 
performance. The median interquartile range CRP mg/L was 
4.3 (3.0–8.4).
Multiple linear regression analysis indicates that ceHb, 
PaO2, and P50 were independently and signiﬁ  cantly associated 
with blood CRP, (R2 = 0.52, p  0.0001). In Table 2, beta 
coefficients, standard errors, t values and p values are 
reported. An even stronger association was found when ceHb, 
PaO2, and P50 were replaced by PaO2x (R2 = 0.62, p  0.0001), 
see Table 3. The speciﬁ  c contribution of PaO2x to CRP 
variability was 56%.
Discussion
C-reactive protein is recognized as a biomarker of the 
systemic inﬂ  ammatory response that characterizes patients 
with COPD (Agustí et al 2003; Schols et al 1996; Gan 
et al 2004). The results of our study conﬁ  rm previous data 
(Broekhuizen et al 2006; Schols et al 1996; Pinto-Plata et al 
2006) that CRP levels are increased in stable COPD patients, 
and provide the novel ﬁ  nding of a strong association between 
reduced “oxygen extractivity” and CRP blood level in stable 
disease condition.
The term “oxygen extractivity” originally proposed by 
Siggaard-Andersen and colleagues (1995) indicates the 
property which allows tissues to extract the usual amount 
of oxygen without a fall in oxygen tension below the usual 
venous level. This is measured along the shape of the oxygen 
binding curve, and quantiﬁ  ed as oxygen extraction tension 
(PaO2x) (Siggaard-Andersen et al 1984). PaO2x describes 
disturbances in oxygen availability depending on arterial 
oxygen tension, hemoglobin oxygen afﬁ  nity and hemoglobin 
oxygen binding capacity, and reﬂ  ects adjustments of cardiac 
output to maintain normal venous oxygen tension, if oxygen 
consumption is normal (Ringsted et al 1990). Thus, we take 
PaO2x as a convenient estimation of the bio-energetic process 
of the convective/diffusive oxygen transport from the lung 
to tissues (Siggard-Andersen et al 1995).
The ﬁ  nding of a strong association between CRP and 
PaO2x, as assessed by the Siggaard-Andersen’s algorithm 
(Siggard-Andersen and Siggard-Andersen 1990), suggests 
a pathogenic link between systemic inflammation and 
reduced oxygen extractivity at tissue level. This result is also 
supported by the ﬁ  nding of a signiﬁ  cant and independent 
predictive value of PaO2 after adjustment for ceHb, P50, age, 
and sex.
These data are not in contrast with those of de Torres 
and colleagues (2006), who report that CRP blood levels 
best correlate with PaO2 in 130 stable COPD patients. 
Furthermore, dependence of PaO2x on hemoglobin oxygen 
afﬁ  nity, hemoglobin oxygen capacity, and PaO2 forwards 
the idea that oxygenation state of hemoglobin, and total 
number of hemoglobin molecules play a regulatory role 
on peripheral oxygen availability, together with arterial 
hypoxemia.
Previous studies (Filley et al 1968; Burrows et al 1972) 
indicated that COPD patients with a low cardiac output 
pattern have more problems with tissue oxygenation during 
exercise than is apparent from their arterial hypoxemia at 
rest, and that tissue hypoxia may account at least in part for 
muscle weakness and impaired performance during physi-
cal activity. This issue has been further addressed by Schols 
et al (Schols et al 1996) who suggested the notion of a link 
between CRP and impaired exercise capacity and distress 
due to respiratory symptoms. Moreover, González-Alonso 
Table1 Clinical and physiologic characteristics of 44 patients with 
stable COPD
Mean (SD) Range
Age, year 68.7 8.6 49–83
BMI, Kg/m2 26.4 4.3 18–35
FEV1, % predicted 47.9 20.9 12–76
MMRC-D, point 2.7 1.0 1–4
6MWD m 298 112 80–500
BODE, points 4.6 2.7 2–10
TLCO, % predicted 49.3 22.4 6–75
tHb, g/dl 14.2 1.8 10–17
FCOHb, % 2.3 0.8 1.6–5.4
FMetHb, % 0.6 0.3 0.6–1.0
FO2Hb, % 90.6 3.7 83–95
sO2, % 92.8 3.8 85–96
PaCO2, mmHg 40.5 6.7 27–53
PaO2, mmHg 63.8 10.4 42–86
PaO2x, mmHg 30.2 2.3 24–33
P50, mmHg 23.2 1.9 18–26
Abbreviations: BMI, body mass index; BODE, BMI, degree of airﬂ  ow obstruction, 
dyspnea, and exercise capacity index; COPD, chronic obstructive pulmonary disease; 
FEV1, forced expiratory volume in one second; FCOHb, fraction of carboxyhemoglobin; 
FMetHb, fraction of metahemoglobin; FO2Hb, fraction of oxyhemoglobin; MMRC-D, 
scores on the Modiﬁ  ed Medical Research Council dyspnea scale; PaCO2, arterial 
carbon dioxide tensions; PaO2, arterial oxygen tension; PaO2x, oxygen extraction 
tension; P50, oxygen half saturation tension; sO2, arterial oxygen saturation; tHb, total 
hemoglobin; 6MWD, distance walked in six minutes.International Journal of COPD 2008:3(4) 749
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and colleagues (2006) reported that local regulation of 
skeletal muscle blood ﬂ  ow and O2 delivery primarily senses 
alterations in the oxygenation state of hemoglobin, sug-
gesting an important role of blood O2 gradients in muscle 
microcirculatory control. Our ﬁ  ndings further emphasize 
these concepts. They deserve further attention to unravel 
molecular responses elicited by tissue hypoxia within the 
lung, the systemic circulation, and the muscles, such as the 
hypothesized metabolic uncoupling between the citric acid 
cycle and the electron transport chain at mitochondria level in 
patients with COPD and chronic respiratory failure (Chance 
et al 1986; Sauleda et al 1998).
Recent studies (Kishimoto et al 1989; Jakobsson 
1990; Maltais et al 1996; Yu et al 1998; Semenza 2000; 
Takabatake et al 2000; Engelen et al 2000; Keller et al 
2001) have begun to delineate pathophysiology of hypoxic 
chronic lung diseases in terms of changes in gene expression 
that are mediated by transcription factors like HIF1, tumor 
necrosis factor system and nuclear factor interleukin (IL)-
6, among the others. As the pro-inﬂ  ammatory cytokine 
IL-6 largely regulates plasma concentrations of CRP, 
the molecular mechanisms that link CRP blood levels 
and tissue hypoxia seem to be a crucial point for a better 
understanding of the origin of systemic inﬂ  ammatory 
process in COPD.
Haagobian and colleagues (2006) documented the 
association between IL-6 mediated increase of CRP and 
either hypoxia, or exercise, or caloric deﬁ  cit in normal 
subjects, who exercise at high altitude. Furthermore, in 
healthy subjects exposed at high altitude, a moderate increase 
of CRP levels is reported to follow the upregulation of both 
cytokine IL-6 and interleukin-1 receptor antagonist (IL-1ra), 
arguing for the onset of a low-grade acute phase response to 
an inﬂ  ammatory stimulus such as hypoxia at high altitude 
(Hartmann et al 2000). Similarly, in our COPD patients 
the reported increase of rest blood CRP levels below the 
range expected for acute inﬂ  ammation invites speculation 
on a low-grade chronic IL-6 release in response to chronic 
hypoxia. The decreased CRP levels and IL-6 and spontaneous 
production of IL-6 by monocytes by n-CPAP in patients 
with obstructive sleep apnea syndrome (OSAS) might 
provide another evidence supporting this idea in relation to 
intermittent hypoxia (Yokoe et al 2003).
The exclusion from the analysis of about 2/3 of the 
patients with COPD according to the criteria detailed in 
Figure 1 could be regarded as a potential limitation of 
the study. However, out of 101 patients excluded from 
the analysis, 52 had a diagnosed cardiovascular disease. 
Therefore, the percentage of COPD patients showing the 
presence of cardiovascular risk factors or diseases (52%) does 
not differ from previously published data (de Torres et al 
2006). Thus, we are conﬁ  dent that the patients included in 
the analysis were also representative of the general COPD 
population.
Table 2 Multiple linear regression analysis with CRP as the dependent variable
Independent variable Beta coefﬁ  cient Standard error T value P value
ceHb, g/dl −0.063 0.027 −2.32 0.025
PaO2, mmHg −0.028 0.006 −4.59 0.0001
P50, mmHg −0.150 0.033 −4.50 0.0001
Sex, M/F −0.098 0.127 −0.77 0.45
Age, yr −0.015 0.005 −2.67 0.011
Intercept 8.006 1.241 6.45 0.0001
Note: R2 = 0.52.
Abbreviations: ceHb, hemoglobin oxygen binding capacity; CRP, C-reactive protein; PaO2, arterial oxygen tension; P50, oxygen half saturation tension.
Table 3 Multiple linear regression analysis with CRP as the dependent variable
Independent variable Beta coefﬁ  cient Standard error T value P value
PaO2x, mmHg −0.139 0.020 −6.91 0.0001
Sex, M/F −0.089 0.106 −0.84 0.41
Age, yr −0.010 0.005 −1.98 0.054
Intercept 5.621 0.643 8.73 0.0001
Note: R2 = 0.62.
Abbreviations: CRP, C-reactive protein; PaO2x, oxygen extraction tension.International Journal of COPD 2008:3(4) 750
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Conclusion
Our ﬁ  ndings clearly indicate that systemic inﬂ  ammation is 
strongly related to reduced oxygen extractivity, and presumably 
tissue hypoxia, throughout the interplay of either intrapulmonary 
oxygen transport and blood supply mechanisms, or systemic 
regulatory aspects of hemoglobin oxygen transport. Our data 
allow some speculation on how the responses to chronic expo-
sure to low oxygen concentrations have evolved into adaptive 
mechanisms operating at tissue level. To the extent that under 
conditions of tissue hypoxia these responses also promote a 
systemic damage, COPD would become a key element boosting 
other systemic inﬂ  ammatory processes. As a practical implica-
tion, the improvement of tissue oxygen availability becomes a 
central therapeutic option to modulate the severity of systemic 
inﬂ  ammatory process in patients with COPD.
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